ELVN Stock Summary and Trading Ideas (Enliven Therapeutics | NASDAQ:ELVN)

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.

As of September 25, 2026, ELVN stock price declined to $44.75 with 921,811 million shares trading.

ELVN has a beta of 1.06, meaning it tends to be more sensitive to market movements. ELVN has a correlation of 0.02 to the broad based SPY ETF.

ELVN has a market cap of $3.20 billion. This is considered a Mid Cap stock.

In the last 3 years, ELVN traded as high as $62.32 and as low as $9.80.

The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

ELVN has outperformed the market in the last year with a return of +141.0%, while the SPY ETF gained +18.4%. However, in the most recent history, ELVN shares have underperformed the stock market with its stock returning -8.9% in the last 3 month period and -17.6% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.

ELVN support price is $43.78 and resistance is $46.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.